<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Syntara Limited — News on 6ix</title>
    <link>https://6ix.com/company/syntara-limited</link>
    <description>Latest news and press releases for Syntara Limited on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 29 Apr 2026 04:42:04 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/syntara-limited" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836697c78dffbe2df15f224.webp</url>
      <title>Syntara Limited</title>
      <link>https://6ix.com/company/syntara-limited</link>
    </image>
    <item>
      <title>$8m placement and share purchase plan</title>
      <link>https://6ix.com/company/syntara-limited/news/dollar8m-placement-and-share-purchase-plan</link>
      <guid isPermaLink="true">https://6ix.com/company/syntara-limited/news/dollar8m-placement-and-share-purchase-plan</guid>
      <pubDate>Wed, 29 Apr 2026 04:42:04 GMT</pubDate>
      <description>$8m placement and share purchase plan</description>
    </item>
    <item>
      <title>Continuation of trading halt</title>
      <link>https://6ix.com/company/syntara-limited/news/continuation-of-trading-halt-4</link>
      <guid isPermaLink="true">https://6ix.com/company/syntara-limited/news/continuation-of-trading-halt-4</guid>
      <pubDate>Tue, 28 Apr 2026 06:27:03 GMT</pubDate>
      <description>Continuation of trading halt</description>
    </item>
    <item>
      <title>Half Year Report and Appendix 4D</title>
      <link>https://6ix.com/company/syntara-limited/news/half-year-report-and-appendix-4d-3</link>
      <guid isPermaLink="true">https://6ix.com/company/syntara-limited/news/half-year-report-and-appendix-4d-3</guid>
      <pubDate>Thu, 26 Feb 2026 02:54:23 GMT</pubDate>
      <description>Half Year Report and Appendix 4D</description>
    </item>
    <item>
      <title>Quarterly Activities/Appendix 4C Cash Flow Report</title>
      <link>https://6ix.com/company/syntara-limited/news/quarterly-activitiesappendix-4c-cash-flow-report-88</link>
      <guid isPermaLink="true">https://6ix.com/company/syntara-limited/news/quarterly-activitiesappendix-4c-cash-flow-report-88</guid>
      <pubDate>Thu, 29 Jan 2026 04:22:04 GMT</pubDate>
      <description>Quarterly Activities/Appendix 4C Cash Flow Report</description>
    </item>
    <item>
      <title>Amsulostat and Garvan in MRFF funded pancreatic trial</title>
      <link>https://6ix.com/company/syntara-limited/news/amsulostat-and-garvan-in-mrff-funded-pancreatic-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/syntara-limited/news/amsulostat-and-garvan-in-mrff-funded-pancreatic-trial</guid>
      <pubDate>Wed, 21 Jan 2026 04:21:03 GMT</pubDate>
      <description>Amsulostat and Garvan in MRFF funded pancreatic trial</description>
    </item>
    <item>
      <title>SNT-4728 Phase 2 iRBD Parkinsons UK Trial fully recruited</title>
      <link>https://6ix.com/company/syntara-limited/news/snt-4728-phase-2-irbd-parkinsons-uk-trial-fully-recruited</link>
      <guid isPermaLink="true">https://6ix.com/company/syntara-limited/news/snt-4728-phase-2-irbd-parkinsons-uk-trial-fully-recruited</guid>
      <pubDate>Thu, 08 Jan 2026 03:51:04 GMT</pubDate>
      <description>SNT-4728 Phase 2 iRBD Parkinsons UK Trial fully recruited</description>
    </item>
    <item>
      <title>Skin scarring program to progress on positive Phase1a result</title>
      <link>https://6ix.com/company/syntara-limited/news/skin-scarring-program-to-progress-on-positive-phase1a-result</link>
      <guid isPermaLink="true">https://6ix.com/company/syntara-limited/news/skin-scarring-program-to-progress-on-positive-phase1a-result</guid>
      <pubDate>Wed, 26 Nov 2025 03:27:07 GMT</pubDate>
      <description>Skin scarring program to progress on positive Phase1a result</description>
    </item>
    <item>
      <title>Quarterly Shareholder Report and Appendix 4C</title>
      <link>https://6ix.com/company/syntara-limited/news/quarterly-shareholder-report-and-appendix-4c</link>
      <guid isPermaLink="true">https://6ix.com/company/syntara-limited/news/quarterly-shareholder-report-and-appendix-4c</guid>
      <pubDate>Tue, 28 Oct 2025 01:51:07 GMT</pubDate>
      <description>Quarterly Shareholder Report and Appendix 4C</description>
    </item>
    <item>
      <title>Positive top-line Phase 2a data confirms competitive profile</title>
      <link>https://6ix.com/company/syntara-limited/news/positive-top-line-phase-2a-data-confirms-competitive-profile</link>
      <guid isPermaLink="true">https://6ix.com/company/syntara-limited/news/positive-top-line-phase-2a-data-confirms-competitive-profile</guid>
      <pubDate>Tue, 30 Sep 2025 02:47:10 GMT</pubDate>
      <description>Positive top-line Phase 2a data confirms competitive profile</description>
    </item>
    <item>
      <title>Preliminary Final Report</title>
      <link>https://6ix.com/company/syntara-limited/news/preliminary-final-report-209</link>
      <guid isPermaLink="true">https://6ix.com/company/syntara-limited/news/preliminary-final-report-209</guid>
      <pubDate>Thu, 28 Aug 2025 08:16:06 GMT</pubDate>
      <description>Preliminary Final Report</description>
    </item>
    <item>
      <title>Guidance from FDA on amsulostat clinical progression</title>
      <link>https://6ix.com/company/syntara-limited/news/guidance-from-fda-on-amsulostat-clinical-progression</link>
      <guid isPermaLink="true">https://6ix.com/company/syntara-limited/news/guidance-from-fda-on-amsulostat-clinical-progression</guid>
      <pubDate>Mon, 11 Aug 2025 04:09:14 GMT</pubDate>
      <description>Guidance from FDA on amsulostat clinical progression</description>
    </item>
    <item>
      <title>Reinstatement to Quotation</title>
      <link>https://6ix.com/company/syntara-limited/news/reinstatement-to-quotation-118</link>
      <guid isPermaLink="true">https://6ix.com/company/syntara-limited/news/reinstatement-to-quotation-118</guid>
      <pubDate>Mon, 04 Aug 2025 04:00:12 GMT</pubDate>
      <description>Reinstatement to Quotation</description>
    </item>
    <item>
      <title>Suspension from Quotation</title>
      <link>https://6ix.com/company/syntara-limited/news/suspension-from-quotation-134</link>
      <guid isPermaLink="true">https://6ix.com/company/syntara-limited/news/suspension-from-quotation-134</guid>
      <pubDate>Fri, 01 Aug 2025 03:51:12 GMT</pubDate>
      <description>Suspension from Quotation</description>
    </item>
    <item>
      <title>Quarterly Appendix 4C Cash Flow Report</title>
      <link>https://6ix.com/company/syntara-limited/news/quarterly-appendix-4c-cash-flow-report-8</link>
      <guid isPermaLink="true">https://6ix.com/company/syntara-limited/news/quarterly-appendix-4c-cash-flow-report-8</guid>
      <pubDate>Fri, 01 Aug 2025 02:37:27 GMT</pubDate>
      <description>Quarterly Appendix 4C Cash Flow Report</description>
    </item>
    <item>
      <title>Quarterly Shareholder Report</title>
      <link>https://6ix.com/company/syntara-limited/news/quarterly-shareholder-report</link>
      <guid isPermaLink="true">https://6ix.com/company/syntara-limited/news/quarterly-shareholder-report</guid>
      <pubDate>Wed, 30 Jul 2025 04:07:44 GMT</pubDate>
      <description>Quarterly Shareholder Report</description>
    </item>
    <item>
      <title>New positive interim data in Phase 2 study of SNT-5505</title>
      <link>https://6ix.com/company/syntara-limited/news/new-positive-interim-data-in-phase-2-study-of-snt-5505</link>
      <guid isPermaLink="true">https://6ix.com/company/syntara-limited/news/new-positive-interim-data-in-phase-2-study-of-snt-5505</guid>
      <pubDate>Fri, 13 Jun 2025 02:57:13 GMT</pubDate>
      <description>New positive interim data in Phase 2 study of SNT-5505</description>
    </item>
    <item>
      <title>SNT-5505 awarded US FDA Fast Track designation</title>
      <link>https://6ix.com/company/syntara-limited/news/snt-5505-awarded-us-fda-fast-track-designation</link>
      <guid isPermaLink="true">https://6ix.com/company/syntara-limited/news/snt-5505-awarded-us-fda-fast-track-designation</guid>
      <pubDate>Tue, 10 Jun 2025 03:24:20 GMT</pubDate>
      <description>SNT-5505 awarded US FDA Fast Track designation</description>
    </item>
    <item>
      <title>Quarterly Activities Report</title>
      <link>https://6ix.com/company/syntara-limited/news/quarterly-activities-report-117</link>
      <guid isPermaLink="true">https://6ix.com/company/syntara-limited/news/quarterly-activities-report-117</guid>
      <pubDate>Wed, 30 Apr 2025 03:24:27 GMT</pubDate>
      <description>Quarterly Activities Report</description>
    </item>
    <item>
      <title>Acceleration of skin scarring program</title>
      <link>https://6ix.com/company/syntara-limited/news/acceleration-of-skin-scarring-program</link>
      <guid isPermaLink="true">https://6ix.com/company/syntara-limited/news/acceleration-of-skin-scarring-program</guid>
      <pubDate>Tue, 18 Mar 2025 01:40:10 GMT</pubDate>
      <description>Acceleration of skin scarring program</description>
    </item>
    <item>
      <title>Equity Raising Presentation</title>
      <link>https://6ix.com/company/syntara-limited/news/equity-raising-presentation-20</link>
      <guid isPermaLink="true">https://6ix.com/company/syntara-limited/news/equity-raising-presentation-20</guid>
      <pubDate>Thu, 12 Dec 2024 04:21:03 GMT</pubDate>
      <description>Equity Raising Presentation</description>
    </item>
  </channel>
</rss>